Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/17/2008

KENILWORTH, N.J., April 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced today that final results of the IDEAL study as well as from several other clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy will be presented at the European Association for the Study of the Liver (EASL) 43rd annual meeting in Milan, Italy, April 23-27. PEGINTRON combination therapy is a current standard of care in the treatment of chronic hepatitis C. A total of 36 data presentations, including nine oral presentations, highlighting Schering-Plough hepatitis medications will be presented at EASL 2008.

The IDEAL (Individualized Dosing Efficacy vs. flat dosing to Assess optimaL pegylated interferon therapy) study is the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C: PEGINTRON and REBETOL combination therapy vs. Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) combination therapy,(1) as well as a lower dose of PEGINTRON plus REBETOL in an investigational combination regimen. Pegasys and Copegus were dosed in accordance with their approved U.S. labeling in this study of more than 3,000 U.S. genotype 1 patients. Results showed that sustained virologic response (SVR), the primary endpoint of the study, was similar for all three treatment regimens. The study also showed in a secondary endpoint that fewer patients treated with both PEGINTRON regimens relapsed after the end of treatment compared to those receiving Pegasys and Copegus.

Final results will be presented for the EPIC3 study, in which more than 2,000 hepatit
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
4. Schering-Plough Reports Top-Line Results of the IDEAL Study
5. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
6. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
7. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
8. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...ewswire/ -- Women,s sexual health company, TivaMed...e as it prepares for a 2010 launch of its Viveve s...veve is a name that we believe captures the essenc...said Kerry Pope, Viveve,s president and chief exec...ing women restore their sense of fulfillment and s...
(Date:11/9/2009)...swire/ -- Access MediQuip, LLC, the nation,s first...dical device management solutions to the healthcar...its corporate headquarters to Lake Mary, Florida. ...growth, includes a major expansion of the Primera ...uary 2010 and relocation and expansion of the Hous...
(Date:11/9/2009)...wire/ -- Decision Resources, one of the world,s le...al and healthcare issues, finds that, in 2008, hum...ting therapies -- which include Roche/Chugai,s Her...Tyverb -- were the highest-selling drug class in b...tin and Tykerb/Tyverb and the expected launches of...
Breaking Medicine Technology:Women's Sexual Health Company Changes Name in Preparation for Market Entry 2Access MediQuip Moves Company Headquarters to Lake Mary, Florida 2Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018 2American Medical Experts Offers New Reduced Flat Rates for Complete Case Reviews 28 24695 29 and Expert Witness Reports 28 24995 29 49705 1American Medical Experts Offers New Reduced Flat Rates for Complete Case Reviews 28 24695 29 and Expert Witness Reports 28 24995 29 49705 2American Medical Experts Offers New Reduced Flat Rates for Complete Case Reviews 28 24695 29 and Expert Witness Reports 28 24995 29 49705 3American Medical Experts Offers New Reduced Flat Rates for Complete Case Reviews 28 24695 29 and Expert Witness Reports 28 24995 29 49705 4Patients Spent an Average of Four Hours and Three Minutes in U S Emergency Departments in 2008 According to Latest Press Ganey Report 49699 1Patients Spent an Average of Four Hours and Three Minutes in U S Emergency Departments in 2008 According to Latest Press Ganey Report 49699 2Patients Spent an Average of Four Hours and Three Minutes in U S Emergency Departments in 2008 According to Latest Press Ganey Report 49699 3Patients Spent an Average of Four Hours and Three Minutes in U S Emergency Departments in 2008 According to Latest Press Ganey Report 49699 4Patients Spent an Average of Four Hours and Three Minutes in U S Emergency Departments in 2008 According to Latest Press Ganey Report 49699 5Patients Spent an Average of Four Hours and Three Minutes in U S Emergency Departments in 2008 According to Latest Press Ganey Report 49699 6Patients Spent an Average of Four Hours and Three Minutes in U S Emergency Departments in 2008 According to Latest Press Ganey Report 49699 7Patients Spent an Average of Four Hours and Three Minutes in U S Emergency Departments in 2008 According to Latest Press Ganey Report 49699 8Fruit fly steps in to fight human disease 12735 1Fruit fly steps in to fight human disease 12735 2
...,Pharmaceuticals, Inc. (Nasdaq: BCRX ) today repo...orodesine HCl, the Company,s lead anti-cancer,comp...as and lymphomas., Madeline Duvic, M.D., Deputy C...derson Cancer Center presented interim data from t...l in the treatment of subjects,with refractory cut...
...ACR20, ACR50 & ACR70 Results, SOUTH SAN FRANCICSO...sdaq: RIGL ) today announced that its oral syk,ki...nstrated statistically,significant results in trea...tly completed Phase 2 clinical trial. Groups treat...ice daily), showed higher ACR20, ACR50,ACR70 and D...
Other Medicine Technology:Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 2Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 3Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 4Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 2Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 3Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 4Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 5Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 6
(Date:11/9/2009)...le have tried to read Charles Darwin,s "Origin of ...nniversary this month, but gave up. , For them a...about, help by way of a new book is at hand. , W...k is the author of "The Origin Then and Now: A...(Princeton University Press, 2009), which makes Da...
(Date:11/9/2009)..., but not all agree , , MONDAY, Nov. 9 (...olution might have soothing short-term benefits, b...ions in the long run by stripping your nose of cri...we are removing the bad mucus but, unfortunately, ...the antimicrobial agents as well," said Dr. Talal ...
(Date:11/9/2009)...quo;s Today Show featured a return of the Berns Tr...day Nov. 6th 2009, The segment followed up with C...pearance on the Today Show on May 28th 2009 in whi...heir treatments by Dr. Jill Waibel of Miami, FL wi... (PRWEB) November 9, 2009 -- N...
(Date:11/9/2009)...ver Career College launches month-long clothing dr..., BC (Vocus) November 9, 2009 -- The students and ...gging through their closets to find clothing to. N...same in order to help women and children in need.,...ommunity here on campus amongst our students, staf...
(Date:11/9/2009)...wire-USNewswire/ --- The U.S. Centers for Disease ...Pennsylvania Coalition Against Rape $1.5 million d...g its National Sexual Violence Resource Center (NS...00 to serve as the nation,s principle center for c...formation and resources about all forms of sexual ...
Breaking Medicine News(10 mins):Health News:Book by UC Riverside biologist explains Darwin's 'Origin of Species' 2Health News:Sinus Rinses May Do More Harm Than Good 2Health News:Sinus Rinses May Do More Harm Than Good 3Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 2Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 3Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 4Health News:Surrey College Students Collect Clothing for Women and Children 2Health News:CDC Awards Vital Prevention Funding to National Sexual Violence Resource Center 2
...BME (BioMedical Enterprises,Inc.), a privately hel...,shape memory implant technology, today announced ...tinol implant designed for internal fixation of,bo...aple changes shape when heated above body temperat...
...sland research is turning conventional wisdom on i... , Professor Bill von Hippel, from UQ,s School o... people,s age and their social satisfaction and he...Hippel measured social activities and social satis...
...ol of risk factors, less likely to get cholesterol...Day News) -- Women with type 2 diabetes and heart ...t they need than men, making their ability to cont...in San Francisco, probably explains why death from...
...June 16 NightHawk,Radiology Holdings, Inc. (Nasda...tions to radiology groups and hospitals throughout... results of its modified Dutch auction,tender offe...hares were properly tendered and not withdrawn at ...
... June 16 Cardiva Medical, Inc., a,privately held ...ang,Catalyst(TM) System announces that it will pre...atalyst(TM) II System and completion of its US,sal...technology investment and partnering conference he...
...pers Get a Campaign Bandana, Dog Owners Get an O...other Diseases, DENVER, June 16 Camp Bow Wow, th...vernight camp, has launched a fund raising,effort ...eases. Beginning June 16 at 26 Camp Bow Wow,locati...
Other Medicine News:Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant 2Health News:Less Intensive Treatment Given Diabetic Women With Heart Disease 2Health News:NightHawk Radiology Holdings, Inc. Announces Preliminary Results of Its Tender Offer; NightHawk Expects to Purchase 2,367,438 Shares of Its Common Stock at $8.05 per Share 2Health News:NightHawk Radiology Holdings, Inc. Announces Preliminary Results of Its Tender Offer; NightHawk Expects to Purchase 2,367,438 Shares of Its Common Stock at $8.05 per Share 3Health News:Cardiva Medical, Inc. to Present at the 'Investment In Innovation (In3) Medical Device Summit' on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion 2Health News:Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundation's Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Minnesota Participating 2
...offered as 1-piece or modular, in regular or extra...omized with handles of choice and other options su...tandard patterns are available from Mediflex stock...s. , Please Note: Individual instrument componen...
...offered as 1-piece or modular, in regular or extra...omized with handles of choice and other options su...tandard patterns are available from Mediflex stock...s. , Please Note: Individual instrument componen...
...offered as 1-piece or modular, in regular or extra...omized with handles of choice and other options su...tandard patterns are available from Mediflex stock...s. , Please Note: Individual instrument componen...
...offered as 1-piece or modular, in regular or extra...omized with handles of choice and other options su...tandard patterns are available from Mediflex stock...s. , Please Note: Individual instrument componen...
Medicine Products: